Mineralys Therapeutics Inc. (NASDAQ:MLYS)’s traded shares stood at 2.43 million during the last session. At the close of trading, the stock’s price was $15.44, to imply an increase of 0.39% or $0.06 in intraday trading. The MLYS share’s 52-week high remains $21.98, putting it -42.36% down since that peak but still an impressive 2.59% since price per share fell to its 52-week low of $15.04. The company has a valuation of $653.73M, with an average of 0.27 million shares in intraday trading volume over the past 10 days and average of 330.40K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Mineralys Therapeutics Inc. (MLYS), translating to a mean rating of 1.60. Of 6 analyst(s) looking at the stock, 0 analyst(s) give MLYS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Mineralys Therapeutics Inc. (NASDAQ:MLYS) trade information
After registering a 0.39% upside in the last session, Mineralys Therapeutics Inc. (MLYS) has traded red over the past five days. The stock hit a weekly high of 17.58 this Friday, 03/17/23, jumping 0.39% in its intraday price action. The 5-day price performance for the stock is -5.16%, and -14.36% over 30 days. With these gigs, the year-to-date price performance is -16.27%.
Analysts on Wall Street suggest a consensus price target of $36.20, implying an increase of 57.35% to the stock’s current value. The extremes give us $27.00 and $45.00 for target low and target high price respectively. As such, MLYS has been trading -191.45% off suggested target high and -74.87% from its likely low.
Mineralys Therapeutics Inc. (MLYS) estimates and forecasts
Looking at statistics comparing Mineralys Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors.
MLYS Dividends
Mineralys Therapeutics Inc. has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Mineralys Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
